A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 7085-7091

  O'Connor, Owen A ^a,b   Stewart, A Keith ^d   Vallone, Marcy ^e   Molineaux, Christopher J ^e   Kunkel, Lori A ^e   Gerecitano, John F ^c   Orlowski, Robert Z ^f  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MAYO CLINIC   (United States)

^e Proteolix Inc   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CARFILZOMIB;

ABDOMINAL PAIN; ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRONCHITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COLON BIOPSY; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATEMESIS; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPESTHESIA; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN INFECTION; SYNCOPE; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OLIGOPEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; TREATMENT OUTCOME;

EID: 72549116835     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0822     Document Type: Article

References (24)

1. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-360
2. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-1657
3. McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11:164-179
4. Sterz J, Hahne JC, Lamottke B, et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008;17:879-895
5. Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997;386:463-471 (Pubitemid 27164066)
6. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 2006;281:8582-8590 (Pubitemid 43847961)
7. Bennett MK, Kirk CJ. Development of proteasome inhibitors in oncology and autoimmune diseases. Curr Opin Drug Discov Devel 2008;11:616-625
8. Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-3964
9. Kane RC, Farrell A, Sridhara R, Pazdur R. United States Food and Drug Administration Approval Summary: Bortezomib for the treatment of progressive Multiple myeloma after one prior therapy. Clin Cancer Res 2006;12:2955-2960 (Pubitemid 43837337)
10. Demo SD, Kirk CJ, Aujay MA, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007;67:6383-6391
11. Groll M, Kim KB, Kairies N, et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis of α′, β′- epoxyketone proteasome inhibitors. J Am Chem Soc 2000;122:1237-1238 (Pubitemid 30117471)
12. Groll M, Huber R, Potts BC. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and amechanism for irreversible binding. J Am Chem Soc 2006;128:5136-5141
13. Demo SD, Buchholz TJ, Laidig GJ, et al. Biochemical and cellular characterization of the novel proteasome inhibitor PR-171 [abstract 1588]. Blood 2005;106.
14. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998;8:333-338
15. Dorsey BD, Iqbal M, Chatterjee S, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008;51:1068-1072
16. Stapnes C, Døskeland AP, Hatfield K, et al. The proteasome inhbitors bortezomib and PR-171 have antiproliferative and proapoptotic effects onprimary human acute myeloid leukaemia cells. Br J Haem 2007;136:814-828 (Pubitemid 46348414)
17. Proteolix Inc. data on file.
18. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123
19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
20. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005;23:667-675
21. Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007;110:3281-3290
22. Orlowski RZ, Stewart AK, Vallone MK, et al. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results [abstract 409]. Blood 2007;110:127a.
23. Alsina M, Trudel S, Vallone M, et al. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies [abstract 411]. Blood 2007;110.
24. 5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008;112:2489-2499